- Home
- CLNN vs PYPD Comparison
CLNN vs PYPD Comparison
Compare CLNN & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- PYPD
- Stock Information
- Founded
- CLNN 2012
- PYPD 2008
- Country
- CLNN United States
- PYPD Israel
- Employees
- CLNN N/A
- PYPD N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- CLNN Health Care
- PYPD Health Care
- Exchange
- CLNN Nasdaq
- PYPD Nasdaq
- Market Cap
- CLNN 35.9M
- PYPD 30.1M
- IPO Year
- CLNN N/A
- PYPD 2020
- Fundamental
- Price
- CLNN $2.57
- PYPD $2.75
- Analyst Decision
- CLNN Strong Buy
- PYPD Strong Buy
- Analyst Count
- CLNN 4
- PYPD 2
- Target Price
- CLNN $55.25
- PYPD $10.50
- AVG Volume (30 Days)
- CLNN 53.5K
- PYPD 13.1K
- Earning Date
- CLNN 05-07-2025
- PYPD 05-07-2025
- Dividend Yield
- CLNN N/A
- PYPD N/A
- EPS Growth
- CLNN N/A
- PYPD N/A
- EPS
- CLNN N/A
- PYPD N/A
- Revenue
- CLNN $342,000.00
- PYPD N/A
- Revenue This Year
- CLNN N/A
- PYPD N/A
- Revenue Next Year
- CLNN $17,399.78
- PYPD N/A
- P/E Ratio
- CLNN N/A
- PYPD N/A
- Revenue Growth
- CLNN N/A
- PYPD N/A
- 52 Week Low
- CLNN $2.57
- PYPD $2.37
- 52 Week High
- CLNN $9.20
- PYPD $5.09
- Technical
- Relative Strength Index (RSI)
- CLNN 19.09
- PYPD 44.19
- Support Level
- CLNN $3.09
- PYPD $2.66
- Resistance Level
- CLNN $4.66
- PYPD $2.97
- Average True Range (ATR)
- CLNN 0.31
- PYPD 0.13
- MACD
- CLNN -0.16
- PYPD -0.02
- Stochastic Oscillator
- CLNN 0.00
- PYPD 20.86
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.